Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2013

01-05-2013 | Research Article

Advanced or metastatic gastric cancer in elderly patients: clinicopathological, prognostic factors and treatments

Authors: Z. Lu, M. Lu, X. Zhang, J. Li, J. Zhou, J. Gong, J. Gao, J. Li, X. Zhang, Y. Li, L. Shen

Published in: Clinical and Translational Oncology | Issue 5/2013

Login to get access

Abstract

Purpose

To analyze the clinicopathological features, prognostic factors, treatment efficacy and safety among elderly patients with advanced or metastatic gastric cancer.

Methods

Three hundred and nineteen patients aged 65 years and older, diagnosed with advanced or metastatic gastric cancer, were followed and data were retrospectively collected, reviewed and analyzed.

Results

The elderly patients carried specific clinicopathological characteristics. Body mass index (BMI), number of metastatic lesions, ascites, Karnofsky performance score (KPS), tumor differentiation grade, lactate dehydrogenase (LDH) level, local treatment, and chemotherapy were the independent prognostic factors. Serum LDH level was superior to the serum CEA level in the prognosis of advanced or metastatic gastric cancer in older patients. Cisplatin-based regimen, chemotherapy cycles, metastatic lesions, LDH level, and supraclavicular lymph node metastasis were the independent prognostic factors in 220 patients receiving chemotherapy. The toxicity was mild and tolerable.

Conclusion

KPS, BMI and a well-differentiated histopathology were factors favoring longer survival, whereas elevated serum LDH and a greater number of metastatic lesions were associated with poor prognosis among those elderly patients. Cisplatin-based chemotherapy provided survival benefits and mild toxicity.
Literature
1.
Munoz N, Franceschi S (1997) Epidemiology of gastric cancer and perspectives for prevention. Salud Publica Mex 39:318–330PubMed
2.
Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150PubMedCrossRef
3.
Bruckner HW, Morris JC, Mansfield P (2000) Neoplasms of the stomach. In: Cancer medicine, 5th edn. BC Decker, Hamilton, pp 1355–1390
4.
Wu CX, Zheng Y, Bao PP et al (2008) Pattern of changing incidence of gastric cancer and its time trend in Shanghai. J Surg Concerpts Pract 13:24–29
5.
Arai T, Takubo K (2007) Clinicopathological and molecular characteristics of gastric and colorectal carcinomas in the elderly. Pathol Int 57:303–314PubMedCrossRef
6.
Cascinu S, Labianca R, Alessandroni P et al (1997) Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 15:3313–3319PubMed
7.
Cascinu S, Scartozzi M, Labianca R et al (2004) High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer [GISCAD]. Br J Cancer 8:1521–1525CrossRef
8.
Habu H, Endo M (1989) Gastric cancer in elderly patients: results of surgical treatment. Hepatogastroenterology 36:71–74PubMed
9.
Fujimoto S, Takahashi M, Ohkubo H et al (1994) Comparative clinicopathologic features of early gastric cancer in young and older patients. Surgery 115:516–520PubMed
10.
Wang JY, Hsieh JS, Huang CJ et al (1996) Clinicopathologic study of advanced gastric cancer without serosal invasion in young and old patients. J Surg Oncol 63:36–40PubMedCrossRef
11.
Saif MW, Makrilia N, Zalonis A et al (2010) Gastric cancer in the elderly: an overview. Eur J Surg Oncol 36:709–717PubMedCrossRef
12.
Arai T, Esaki Y, Inoshita N et al (2004) Pathologic characteristics of gastric cancer in the elderly: a retrospective study of 994 surgical patients. Gastric Cancer 7:154–159PubMedCrossRef
13.
Ishigami S, Natsugoe S, Saihara T et al (1997) Clinical and pathologic features of early gastric cancer in elderly patients. Hepatogastroenterology 44:1164–1168PubMed
14.
Inoshita N, Yanagisawa A, Arai T et al (1998) Pathological characteristics of gastric carcinomas in the very old. Jpn J Cancer Res 89:1087–1092PubMedCrossRef
15.
Wu CW, Lo SS, Shen KH et al (2000) Surgical mortality, survival and quality of life after resection for gastric cancer in the elderly. World J Surg 24:465–472PubMedCrossRef
16.
Maehara Y, Emi Y, Tomisaki S et al (1996) Age-related characteristics of gastric carcinoma in young and elderly patients. Cancer 77:1774–1780PubMedCrossRef
17.
Nielsen J, Aagaard J, Toftgaard C (1985) Gastric cancer with special reference to prognostic factors: a review of 779 cases. Acta Chir Scand 151:49–55PubMed
18.
Chau I, Norman AR, Cunningham D et al (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomised, controlled trials using individual patient data. J Clin Oncol 22:2395–2403PubMedCrossRef
19.
Sudo H, Takagi Y, Katayanagi S et al (2006) Bone metastasis of gastric cancer. Gan To Kagaku Ryoho 33:1058–1060PubMed
20.
Glimelius B, Ekström K, Hoffman K et al (1997) Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163–168PubMedCrossRef
21.
Pyrhönen S, Kuitunen T, Nyandoto P et al (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591PubMedCrossRef
22.
Murad AM, Santiago FF, Petroianu A et al (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37–41PubMedCrossRef
23.
Trumper M, Ross PJ, Cunningham D et al (2006) Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer 42:827–834PubMedCrossRef
24.
Santini D, Graziano F, Catalano V et al (2006) Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. BMC Cancer 6:125PubMedCrossRef
25.
Graziano F, Santini D, Testa E et al (2003) A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. Br J Cancer 89:1428–1432PubMedCrossRef
26.
Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221PubMedCrossRef
27.
Seol YM, Song MK, Choi YJ et al (2009) Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study. Jpn J Clin Oncol 39:43–48PubMedCrossRef
28.
Tsushima T, Hironaka S, Boku N et al (2010) Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer. Gastric Cancer 13:245–250PubMedCrossRef
29.
Lee JL, Kang YK, Kang HJ et al (2008) A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 99:584–590PubMedCrossRef
30.
Tsuji A, Shima Y, Morita S et al (2008) Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study. Anticancer Res 28:1433–1438PubMed
Metadata
Title
Advanced or metastatic gastric cancer in elderly patients: clinicopathological, prognostic factors and treatments
Authors
Z. Lu
M. Lu
X. Zhang
J. Li
J. Zhou
J. Gong
J. Gao
J. Li
X. Zhang
Y. Li
L. Shen
Publication date
01-05-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 5/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0938-4

Other articles of this Issue 5/2013

Clinical and Translational Oncology 5/2013 Go to the issue

Research Article

Clinical report on transarterial neoadjuvant chemotherapy of malignant fibrous histiocytoma in soft tissue

Educational Series – Blue Series

MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications

Educational Series – Red Series

An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents

Erratum

Erratum to: Polymorphisms in HIF-1alpha affect presence of lymph node metastasis and can influence tumor size in squamous-cell carcinoma of the glottic larynx

Brief Research Article

Cone-beam computed tomography dose monitoring during intensity-modulated radiotherapy in head and neck cancer: parotid glands

Research Article

Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits